Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Q3 2023 Earnings Presentation
15 slides from Sanara Medtech's earnings presentation, Nov 13, 2023
Slide 1: Q3 2023 Earnings and Business Update Call
Q3 2023 Earnings and Business Update Call
Slide 2: Disclaimers
Sanara MedTech Disclaimers ‘This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc, (the "Company," "Sanara,” “we,” ‘our" or us"), All
Slide 3: Overview: Commentary on Q3 2023
Sanara MedTech Overview Commentary on Q3 2023 Financial Update (Unaudited) + Highest net revenue quarter in the Company's history ($16.0 million). + Loss before income taxes narrowed from $3.2 million to $1.1 million in Q3 YOY. + Netloss of $1.1 million in Q3 2023 compared to $1.5 million in Q3 2022
Slide 4: Building a Leading Medical Technology Company
Sanara MedTech Building a Leading Medical Technology Company Multi-year Growth Strategy + Rochal asset acquisition (brought R&D in-house) + Launched Cook Biotech Inc, products (expanded product offering) Constructing a leading medical technology platform... * Scendia Biologics acquisition (expanded
Slide 5: Surgical Sales
Sanara MedTech Surgical Sales Q3 2023 Sales Overview (Unaudited) * Q8 rate of sales growth was impacted due to: + Continued ALLOCYTE® supply issues + CellerateRX® usage levels negatively impacted growth in four territories. These territory challenges have been analyzed and appropriate adjustments ha
Slide 6: Surgical Sales (continued)
Sanara MedTech Surgical Sales (continued) Q3 2023 Sales Overview + Sales of soft tissue products were $13.6 million in Q3 (CellerateRX®, FORTIFY TRG® Tissue Repair Graft, FORTIFY FLOWABLE® ECM, and TEXAGEN® Amniotic Membrane Allograft) + Sales of bone fusion products were $2.3 million in Q3 (BIFORM®
Slide 7: BIASURGE Product Launch
Exhibited and launched BIASURGE™ at AAHKS (American Association of Hip and Knee Surgeons) conference in November 2023. First sale in early November 2023. Was trialed prior to launch with physicians and initial feedback has been positive Company believes that this product could be used in any surgery
Slide 8: Collagen Products Asset Acquisition Overview
+ Assets acquired from the sellers include: + Certain 510(k) cleared collagen- based wound care products including CellerateRX® and HYCOL® for human wound care cases. + Nine patents and all of the sellers’ patents pending for collagen products for human wound care uses and five trademarks. ollagen P
Slide 9: Tissue Health Plus (Formerly WounDerm)
Tissue Health Plus (Formerly WounDerm) Post-Acute Value-Based Care Strategy + Exploring ways to accelerate commercialization or find an appropriate partner that can add a value-based component to this strategy. + Total 2023 costs through the end of Q3 2023 were $5M+. 1st value-based wound prevention
Slide 10: Q3 2023 Financial Highlights
Sanara MedTech Q3 2023 Financial Highlights Overview (Unaudited) + Revenue For the three months ended September 30, 2023, we generated net revenue of $16.0 million compared to net revenue of $13.0 million for the three months ended September 30, 2022, a 23% increase from the prior year period. For t
Slide 11: Q3 2023 Financial Highlights (Continued)
Sanara MedTech Q3 2023 Financial Highlights (Continued) Overview (Continued) + R&D Expenses + R&D expenses for the three months ended September 30, 2023, were $1.0 million compared to $1.1 million for the three months ended September 30, 2022. + R&D expenses for the nine months ended September 30, 2
Slide 12: Questions
2 Questions Syelalelae MedTech Evidence Based Healing
Slide 13: Appendix
Appendix Syelalelae MedTech Evidence Based Healing
Slide 14: Non-GAAP Financial Measure
Sanara MedTech Non-GAAP Financial Measure Use of Non-GAAP Financial Measure To supplement the Company's financial information presented in accordance with generally accepted accounting principles in the United States ("GAAP"), we present certain non-GAAP financial measures in this press release and
Slide 15: Reconciliation of GAAP to Non-GAAP Financial Measures
Sanara MedTech Reconciliation of GAAP to Non-GAAP Financial Measures ion of Net Loss to Adjusted EBITDA (Unaudited) Three Months Ended September 30, September 30, 2023 2022 Net Loss $ (1,094,949) $ (1,529,252) Adjustments Interest expense - Term Loan 146,540 : Debt issuance costs amortization 2,055